Sarepta Therapeutics has announced a strategic restructuring plan, including the layoff of approximately 500 employees, representing about one-third of its workforce, as part of efforts to prioritize its pipeline and ensure long-term sustainable growth. This move follows setbacks related to its Duchenne muscular dystrophy gene therapy, Elevidys, which has recently received a black box warning after patient deaths were reported. The company aims to refocus on high-impact programs and expects to achieve significant annual savings as it pivots towards innovative siRNA treatments.